Expression and Prognostic Significance of Cancer/Testis Antigens, MAGE-E۱, GAGE, and SOX-۶, in Glioblastoma: An Immunohistochemistry Evaluation

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 108

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJP-16-2_005

تاریخ نمایه سازی: 14 بهمن 1400

Abstract:

Background & Objectives: Glioblastoma is the most common primary malignancy of the brain, the prognosis of which is poor. Immunotherapy with cancer/testis (CT) antigens is a novel therapeutic approach for glioblastoma. This study aimed to investigate the expression rate of MAGE-E۱, GAGE, and SOX-۶ in glioblastoma tumors using the immunohistochemistry (IHC) method. Materials & Methods: Expression of MAGE-E۱, GAGE, and SOX-۶ were determined by IHC in ۵۰ paraffin blocks of glioblastoma. The results were compared between variables including age, gender, tumor location, and Karnofsky performance status (Kps) score. Survival analysis was also performed. Results: The expression levels of SOX-۶, MAGE-E۱, and GAGE were ۸۲%, ۷۸%, and ۷۶%, respectively. The relationship between CT antigens and age, gender, and tumor location was not significant, while the association between MAGE-E۱ expression and age was statistically significant (p =۰.۰۰۲). High expression levels of SOX-۶ and MAGE-E۱ were associated with low Kps scores (p =۰.۰۳۴ and p <۰.۰۰۱, respectively). Survival analysis showed that age >۴۰ and Kps score p =۰.۰۰۵ and p =۰.۰۱۸, respectively). Expression of MAGE-E۱ and GAGE was negatively associated with overall ۲-year survival (p =۰.۰۰۱ and p =۰.۰۲۱, respectively). Conclusion: The expression of all the three CT antigens, especially MAGE-E۱ and SOX-۶, was high in patients with glioblastoma. It can be concluded that these markers are ideal targets for immunotherapy in these patients. MAGE-E۱ and SOX-۶ can be considered as important markers in determining the prognosis of glioblastoma.

Authors

- -

Department of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran

- -

Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

- -

Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran

- -

Department of Pathology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

- -

Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

- -

Department of Statistics, Ferdowsi University of Mashhad, Mashhad, Iran

- -

Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

- -

Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Young RM, Jamshidi A, Davis G, Sherman JH. Current trends ...
  • Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical ...
  • Old LJ. Cancer/testis (CT) antigens-a new link between gametogenesis and ...
  • Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. ...
  • Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, ...
  • Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, ...
  • Stupp R, Hegi ME, Mason WP, van den Bent MJ, ...
  • نمایش کامل مراجع